Evaluation of safety criteria for enoxaparin bridging in patients with left ventricular assist devices in an outpatient care setting
When eligibility criteria for safe bridging were applied, the use of enoxaparin bridging was associated with no major bleeding/thrombotic events during bridging and improved 3-year survival in LVAD patients. Economically, using outpatient enoxaparin resulted in substantial healthcare savings, fewer readmissions, and improved quality of life.
Authors
- Oksana Volod (ORCID: https://orcid.org/0000-0001-6285-7585)
- Jason Jang
- Tram Ngo
- L. Czer (ORCID: https://orcid.org/0000-0001-5744-2625)
- M. Aguillon
- Lee D. Lam (ORCID: https://orcid.org/0000-0002-1305-7642)
- Mignon Gau
- C. Runyan
- Jason Lau
- Konighinn Ludwika Derflingher Hernández
- Ieeshiah Otarola
- N. Huie
- Julie W. Chen
- Robert Cole
- J. Moriguchi
Institutions
- Cedars-Sinai Medical Center (US)
- Cedars-Sinai Smidt Heart Institute (US)
Publication Details
- Journal
- Artificial Organs
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1111/aor.14900
- Citations
- 1
- Primary Topic
- Mechanical Circulatory Support Devices
- Type
- article
- Field-Weighted Citation Impact
- 0.18